SCHEMBL5787703

SCHEMBL5787703

CCOC(=O)c1ccc(NC(=C2C(=O)Nc3cc(-c4ccccc4C)ccc32)c2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.49
SMN1; SMN2 Q16637 5/20 0.47
GAA P10253 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
MEN1 O00255 8/20 0.45
KMT2A Q03164 8/20 0.45
ALDH1A1 P00352 3/20 0.45
MAPT P10636 5/20 0.45
TP53 P04637 2/20 0.44
THRB P10828 1/20 0.44
NAMPT P43490 1/20 0.44
NPSR1 Q6W5P4 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
LMNA P02545 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5787702 1.00 RXFP1 (0.49) RXFP1SMN1; SMN2GAANPC1RAB9A
SCHEMBL6320998 0.88 SMN1; SMN2 (0.56) RXFP1SMN1; SMN2GAANPC1RAB9A
SCHEMBL6320993 0.88 SMN1; SMN2 (0.56) RXFP1SMN1; SMN2GAANPC1RAB9A
SCHEMBL2570973 0.87 RXFP1 (0.52) RXFP1SMN1; SMN2GAANPC1RAB9A
SCHEMBL2570974 0.87 RXFP1 (0.52) RXFP1SMN1; SMN2GAANPC1RAB9A
SCHEMBL481166 0.86 RXFP1 (0.51) RXFP1SMN1; SMN2GAANPC1RAB9A
SCHEMBL481167 0.86 RXFP1 (0.51) RXFP1SMN1; SMN2GAANPC1RAB9A
SCHEMBL4485304 0.86 SMN1; SMN2 (0.50) RXFP1SMN1; SMN2GAANPC1RAB9A
SCHEMBL4485301 0.86 SMN1; SMN2 (0.50) RXFP1SMN1; SMN2GAANPC1RAB9A
SCHEMBL2569219 0.86 RXFP1 (0.51) RXFP1SMN1; SMN2GAANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1212318-B1 SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA (DE) 2006-01-25 EP disclosed
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-01-13 US disclosed
US-6794395-B1 Substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-09-21 US disclosed
EP-1212318-A1 SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS Boehringer Ingelheim Pharma KG (DE) 2002-06-12 EP disclosed
WO-2001016130-A1 SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments CCNE1, CDK1, CCNI RXFP1 1214/4885SMN1; SMN2 4537/4885GAA 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.